Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification | Zendy

Rita Golfieri | Zendy; Irene Bargellini | Zendy; Carlo Spreafico | Zendy; Franco Trevisani | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification

Author(s) -

Rita Golfieri,

Irene Bargellini,

Carlo Spreafico,

Franco Trevisani

Publication year - 2018

Publication title -

liver cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.916

H-Index - 34

eISSN - 2235-1795

pISSN - 1664-5553

DOI - 10.1159/000489791

Subject(s) - medicine , hepatocellular carcinoma , liver cancer , stage (stratigraphy) , radiology , liver function , portal vein thrombosis , sorafenib , embolization , gastroenterology , oncology , portal vein , paleontology , biology

The Barcelona Clinic Liver Cancer (BCLC) intermediate and advanced stages (BCLC B and C) of hepatocellular carcinoma (HCC) both include heterogeneous populations. Patients classified as BCLC stage B present with different tumour burdens, and the recommended treatment is transarterial chemoembolization (TACE). A similar heterogeneity of tumour burden and liver function can be found among patients classified as BCLC stage C, which includes diverse clinical features (performance status [PS] 1-2), macrovascular invasion (MVI) including portal vein tumour (PVT) thrombosis, and/or extra-hepatic spread. Nonetheless, the anti-tumoural treatment formally recommended by Western guidelines is systemic therapy with sorafenib.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research